aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Avalo Therapeutics, founded with a mission to address significant unmet clinical needs through precision medicine, is a clinical-stage biopharmaceutical company. The company focuses on discovering, developing, and commercializing targeted therapeutics for immune dysregulation. Avalo's product pipeline includes high-value, first-in-class biologics such as AVTX-, an anti-IL-1β monoclonal antibody for inflammatory diseases, quisovalimab (anti-LIGHT mAb), and AVTX- (BTLA agonist fusion protein).
Notable figures affiliated with Avalo Therapeutics include experienced leaders in biotechnology and pharmaceuticals. The company has garnered attention from prominent investors in the biopharma sector. Key achievements include the acquisition and development of their lead asset, AVTX-, which has shown promise in targeting inflammatory diseases. Avalo's precision medicine approach and innovative pipeline have positioned it as a significant player in the biopharmaceutical industry, aiming to improve patient outcomes through targeted therapies.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Biopharmaceuticals
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Avalo Therapeutics founded?
Avalo Therapeutics was founded in 2011.
Where is Avalo Therapeutics’s headquarters located?
Avalo Therapeutics’s headquarters is located in Rockville, MD, US.
When was Avalo Therapeutics’s last funding round?
Avalo Therapeutics’s most recent funding round was for $15M (USD) in February 2023.
How many employees does Avalo Therapeutics have?
Avalo Therapeutics has 42 employees as of Feb 6, 2024.
How much has Avalo Therapeutics raised to-date?
As of July 05, 2023, Avalo Therapeutics has raised a total of $46.5M (USD) since Feb 2, 2023.
Add Comparison
Total Raised to Date
$46.5M
USD
Last Update Feb 2, 2023
Last Deal Details
$15M
USD
Feb 2, 2023
Post Ipo Equity
Total Employees Over Time
42
As of Feb 2024
Avalo Therapeutics Address
540 Gaither Road
suite 400
Rockville,
Maryland
20850
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts